Evidence map›Paper›PMID 35008412›Full record

ArticleCancers2022

Cause of Death, Mortality and Occult Blood in Colorectal Cancer Screening.

Lasse Kaalby, Issam Al-Najami, Ulrik Deding, Gabriele Berg-Beckhoff, Robert J C Steele, Morten Kobaek-Larsen, Aasma Shaukat, Morten Rasmussen, Gunnar Baatrup

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Lasse KaalbyDepartment of Surgery, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0002-6721-3604
Issam Al-NajamiDepartment of Surgery, Odense University Hospital, 5000 Odense, Denmark.
Ulrik DedingDepartment of Surgery, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0002-8263-2989
Gabriele Berg-BeckhoffUnit for Health Promotion Research, Department of Public Health, University of Southern Denmark, 6700 Esbjerg, Denmark.ORCID 0000-0003-1614-938X
Robert J C SteeleCentre for Research into Cancer Prevention and Screening, University of Dundee School of Medicine, Dundee DD1 9SY, UK.
Morten Kobaek-LarsenDepartment of Surgery, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0002-5097-9283
Aasma ShaukatGI Section, Minneapolis VA Medical Center and University of Minnesota, Minneapolis, MN 55417, USA.
Morten RasmussenDigestive Disease Center, Bispebjerg University Hospital, 2400 Copenhagen, Denmark.
Gunnar BaatrupDepartment of Surgery, Odense University Hospital, 5000 Odense, Denmark.
University of Southern Denmark · DKBispebjerg Hospital · DKOdense University Hospital · DKUniversity of Dundee · GBUniversity of Minnesota · US

Funding

Danish Cancer Society R100-A6747Odense University Hospital A3472/A2359United States Department of Veterans Affairs 36C24E18P0155University of Southern Denmark
6 · The paper itself

Abstract

Fecal hemoglobin (f-Hb) detected by the guaiac fecal occult blood test (gFOBT) may be associated with mortality and cause of death in colorectal cancer (CRC) screening participants. We investigated this association in a randomly selected population of 20,694 participants followed for 33 years. We followed participants from the start of the Hemoccult-II CRC trial in 1985-1986 until December 2018. Data on mortality, cause of death and covariates were retrieved using Danish national registers. We conducted multivariable Cox regressions with time-varying exposure, reporting results as crude and adjusted hazard ratios (aHRs). We identified 1766 patients with at least one positive gFOBT, 946 of whom died in the study period. Most gFOBT-positive participants (93.23%) died of diseases unrelated to CRC and showed higher non-CRC mortality than gFOBT-negative participants (aHR: 1.20, 95% CI 1.10-1.30). Positive gFOBT participants displayed a modest increase in all-cause (aHR: 1.28, 95% CI: 1.18-1.38), CRC (aHR: 4.07, 95% CI: 3.00-5.56), cardiovascular (aHR: 1.22, 95% CI: 1.07-1.39) and endocrine and hematological mortality (aHR: 1.58, 95% CI: 1.19-2.10). In conclusion, we observed an association between positive gFOBT, cause of death and mortality. The presence of f-Hb in the gFOBT might indicate the presence of systemic diseases.

Indexed as

cause of deathcolorectal cancerfecal hemoglobinmortalityscreening

Identifiers

PMID35008412
PMCPMC8750981
OpenAlexW4206560140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.